Adjuvant PD-1 blockade in resected melanoma: Is preventing recurrence enough? Editorial

  


Authors: Smithy, J. W.; Shoushtari, A. N.
Title: Adjuvant PD-1 blockade in resected melanoma: Is preventing recurrence enough?
Abstract: SUMMARY: Grossmann and colleagues report the results of a large randomized trial demonstrating improved recurrence-free survival with adjuvant pembrolizumab in resected melanoma compared with adjuvant ipilimumab or IFNα2b. However, it remains unclear whether adjuvant immunotherapies extend overall survival as outcomes for patients with advanced melanoma continue to improve. See related article by Grossmann et al., p. 644 (1). ©2022 American Association for Cancer Research.
Journal Title: Cancer Discovery
Volume: 12
Issue: 3
ISSN: 2159-8274
Publisher: American Association for Cancer Research  
Date Published: 2022-03-01
Start Page: 599
End Page: 601
Language: English
DOI: 10.1158/2159-8290.Cd-21-1593
PUBMED: 35257151
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125972224&doi=10.1158%2f2159-8290.CD-21-1593&partnerID=40&md5=045ca548c86408b93d7718687a4f97bb
Notes: Editorial -- Export Date: 1 April 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Alexander Noor Shoushtari
    244 Shoushtari
  2. James William Smithy
    28 Smithy
Related MSK Work